scholarly journals Pulmonary embolism as a cause of cardiac arrest: Hypothermia in post-resuscitation period (cooling therapy)

2013 ◽  
Vol 141 (7-8) ◽  
pp. 519-523
Author(s):  
Vuk Nikovic ◽  
Anton Lagner ◽  
Dejan Kojic

Introduction. Pulmonary embolism as a possible cause of acute heart failure is a potentially fatal condition that can cause death in all age groups. Patients successfully resuscitated after cardiac arrest have a high risk of increased mortality and their poor long?term outcome is often associated with severe neurological complications. Case Outline. This is a case report of a 67?year?old man after a successful cardiopulmonary resuscitation (CPR) which was followed by therapeutic hypothermia (TH). The patient visited the dermatological outpatients? department with clinical presentation of pain and swelling of the right leg, shortness of breath and chest pain. During examination the patient lost consciousness, stopped breathing and had cardiac arrest. ECG was done which registered asystole. We began CPR. After 59 minutes of resuscitation return of heartbeat was achieved. The patient was transported to the Emergency Department. On admission, after computerized tomography (CT) of the chest confirmed massive pulmonary embolism (PE), the patient was administered thrombolytic therapy with Metalyse (tenecteplase) and anti?coagulation therapy (heparin). After stabilization, therapeutic hypothermia was applied. Combination of EMCOOLSpad on the chest and abdomen and cold Ringer lactate 500 ml at 4?C was flushed. Temperature was decreased to 33?C and kept stabile for 24 hours. After eight days the patient was conscious with a minimal neurological deficit. Conclusion. As shown in this case report, and according to the rich experience elsewhere, cooling therapy after out?of?hospital cardiac arrest and successful CRP may be useful in preventing neurological complications.

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Sy Van Hoang ◽  
Anh Tuan Vo ◽  
Kha Minh Nguyen

A 25-year-old pregnant woman presented at 12 weeks of gestation with syncope and shortness of breath caused by massive pulmonary embolism. Due to persistent shock, fibrinolytic therapy with rtPA was administered. After fibrinolysis, clinical and hemodynamic response was excellent. No bleeding and fetal complications were recorded.


CHEST Journal ◽  
2009 ◽  
Vol 136 (4) ◽  
pp. 146S
Author(s):  
Bishav Mohan ◽  
Shibba T. Chhabra ◽  
Naved Aslam ◽  
Gurpreet S. Wander ◽  
Anil K. Kashyap

2019 ◽  
Vol 19 (6) ◽  
pp. 186-189 ◽  
Author(s):  
Toru Miyoshi ◽  
Hideo Kawakami ◽  
Reiko Hori ◽  
Kazuo Nakanishi ◽  
Takehisa Kusumoto ◽  
...  

2020 ◽  
Vol 77 (23) ◽  
pp. 1961-1964 ◽  
Author(s):  
Lisa M Sagardia ◽  
Lisa M Daniels

Abstract Purpose Successful use of alteplase and argatroban to treat a patient with coronavirus disease 2019 (COVID-19)–associated massive pulmonary embolism with cardiac arrest is reported. Summary This case report describes a 42-year-old male with COVID-19 who developed a massive pulmonary embolism resulting in cardiac arrest after suspected failure of low-molecular-weight heparin therapy for a deep venous thrombosis. Administration of two 50-mg doses of intravenous alteplase resulted in return of spontaneous circulation, and low-dose argatroban was used as follow-up anticoagulation therapy without complications. This is the first case report of use of argatroban in a patient with COVID-19 with cardiac arrest–associated massive pulmonary embolism after failure of previous anticoagulation efforts. Conclusion Argatroban may be used as an alternate anticoagulation strategy in COVID-19 patients who fail low-molecular weight therapy. A risk versus benefit discussion should be had regarding appropriateness of therapy as well as dosing. More data is needed to understand the unique hypercoagulable condition in COVID-19 patients as well as research that further highlights the role of argatroban and bivalirudin therapy in this patient population.


Sign in / Sign up

Export Citation Format

Share Document